Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Molecular Basis of the Divergent Immunogenicity of Two Pediatric Tick-Borne Encephalitis Virus Vaccines.

Beck Y, Fritz R, Orlinger K, Kiermayr S, Ilk R, Portsmouth D, Pöllabauer EM, Löw-Baselli A, Hessel A, Kölch D, Howard MK, Barrett PN, Kreil TR.

J Virol. 2015 Dec 9;90(4):1964-72. doi: 10.1128/JVI.02985-15. Print 2016 Feb 15.

2.

Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients.

Fritz R, Hetzelt N, Ilk R, Hohenadl C, van der Velden MV, Aichinger G, Portsmouth D, Kistner O, Howard MK, Barrett PN, Kreil TR.

Open Forum Infect Dis. 2014 Aug 25;1(2):ofu072. doi: 10.1093/ofid/ofu072. eCollection 2014 Sep.

3.

Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs.

Wodal W, Schwendinger MG, Savidis-Dacho H, Crowe BA, Hohenadl C, Fritz R, Brühl P, Portsmouth D, Karner-Pichl A, Balta D, Grillberger L, Kistner O, Barrett PN, Howard MK.

PLoS One. 2015 Feb 26;10(2):e0113963. doi: 10.1371/journal.pone.0113963. eCollection 2015.

4.

An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial.

Wressnigg N, van der Velden MV, Portsmouth D, Draxler W, O'Rourke M, Richmond P, Hall S, McBride WJ, Redfern A, Aaskov J, Barrett PN, Aichinger G.

Clin Vaccine Immunol. 2015 Mar;22(3):267-73. doi: 10.1128/CVI.00546-14. Epub 2014 Dec 24.

5.

Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.

Aichinger G, Grohmann-Izay B, van der Velden MV, Fritsch S, Koska M, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN.

Clin Vaccine Immunol. 2015 Jan;22(1):46-55. doi: 10.1128/CVI.00275-14. Epub 2014 Oct 29.

6.

A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.

Wressnigg N, Barrett PN, Pöllabauer EM, O'Rourke M, Portsmouth D, Schwendinger MG, Crowe BA, Livey I, Dvorak T, Schmitt B, Zeitlinger M, Kollaritsch H, Esen M, Kremsner PG, Jelinek T, Aschoff R, Weisser R, Naudts IF, Aichinger G.

Clin Vaccine Immunol. 2014 Nov;21(11):1490-9. doi: 10.1128/CVI.00406-14. Epub 2014 Sep 3.

7.

Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.

van der Velden MV, Geisberger A, Dvorak T, Portsmouth D, Fritz R, Crowe BA, Herr W, Distler E, Wagner EM, Zeitlinger M, Sauermann R, Stephan C, Ehrlich HJ, Barrett PN, Aichinger G.

Clin Vaccine Immunol. 2014 Jun;21(6):867-76. doi: 10.1128/CVI.00065-14. Epub 2014 Apr 16.

8.

Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice.

Hohenadl C, Wodal W, Kerschbaum A, Fritz R, Howard MK, Farcet MR, Portsmouth D, McVey JK, Baker DA, Ehrlich HJ, Barrett PN, Kreil TR.

Virol J. 2014 Apr 16;11:70. doi: 10.1186/1743-422X-11-70.

9.

MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses.

Hessel A, Savidis-Dacho H, Coulibaly S, Portsmouth D, Kreil TR, Crowe BA, Schwendinger MG, Pilz A, Barrett PN, Falkner FG, Schäfer B.

PLoS One. 2014 Feb 11;9(2):e88340. doi: 10.1371/journal.pone.0088340. eCollection 2014.

10.

Lyme disease vaccination: safety first - authors' reply.

Barrett PN, Crowe BA, Wressnigg N, Portsmouth D, Aichinger G.

Lancet Infect Dis. 2014 Jan;14(1):12-13. doi: 10.1016/S1473-3099(13)70362-1. No abstract available.

PMID:
24355029
11.

Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.

Schwendinger MG, O'Rourke M, Traweger A, Savidis-Dacho H, Pilz A, Portsmouth D, Livey I, Barrett PN, Crowe BA.

PLoS One. 2013 Nov 18;8(11):e79022. doi: 10.1371/journal.pone.0079022. eCollection 2013.

12.

A novel multivalent OspA vaccine against Lyme borreliosis shows promise in Phase I/II studies.

Barrett PN, Portsmouth D.

Expert Rev Vaccines. 2013 Sep;12(9):973-5. doi: 10.1586/14760584.2013.824704. No abstract available.

PMID:
24053389
13.

Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.

van der Velden MV, Fritz R, Pöllabauer EM, Portsmouth D, Howard MK, Kreil TR, Dvorak T, Fritsch S, Vesikari T, Diez-Domingo J, Richmond P, Lee BW, Kistner O, Ehrlich HJ, Barrett PN, Aichinger G.

J Infect Dis. 2014 Jan 1;209(1):12-23. doi: 10.1093/infdis/jit498. Epub 2013 Sep 16.

PMID:
24041789
14.

Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.

Wressnigg N, Pöllabauer EM, Aichinger G, Portsmouth D, Löw-Baselli A, Fritsch S, Livey I, Crowe BA, Schwendinger M, Brühl P, Pilz A, Dvorak T, Singer J, Firth C, Luft B, Schmitt B, Zeitlinger M, Müller M, Kollaritsch H, Paulke-Korinek M, Esen M, Kremsner PG, Ehrlich HJ, Barrett PN.

Lancet Infect Dis. 2013 Aug;13(8):680-9. doi: 10.1016/S1473-3099(13)70110-5. Epub 2013 May 10.

PMID:
23665341
15.

Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development.

Barrett PN, Portsmouth D, Ehrlich HJ.

Expert Rev Vaccines. 2013 Apr;12(4):395-413. doi: 10.1586/erv.13.21. Review.

PMID:
23560920
16.

The need for a new vaccine against lyme borreliosis.

Barrett PN, Portsmouth D.

Expert Rev Vaccines. 2013 Feb;12(2):101-3. doi: 10.1586/erv.12.141. No abstract available.

PMID:
23414400
17.

A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.

Sabarth N, Savidis-Dacho H, Schwendinger MG, Brühl P, Portsmouth D, Crowe BA, Kistner O, Barrett PN, Kreil TR, Howard MK.

Vaccine. 2012 Aug 10;30(37):5533-40. doi: 10.1016/j.vaccine.2012.06.043. Epub 2012 Jun 29.

PMID:
22749797
18.

A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.

Wodal W, Falkner FG, Kerschbaum A, Gaiswinkler C, Fritz R, Kiermayr S, Portsmouth D, Savidis-Dacho H, Coulibaly S, Piskernik C, Hohenadl C, Howard MK, Kistner O, Barrett PN, Kreil TR.

Vaccine. 2012 Jun 29;30(31):4625-31. doi: 10.1016/j.vaccine.2012.04.102. Epub 2012 May 10.

PMID:
22580355
19.

Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.

Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.

Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061. Epub 2012 Apr 1.

PMID:
22475864
20.

A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals.

Ehrlich HJ, Singer J, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Portsmouth D, Kistner O, Barrett PN.

Clin Infect Dis. 2012 Apr;54(7):946-54. doi: 10.1093/cid/cir959. Epub 2012 Jan 19.

21.

Clinical development of a Vero cell culture-derived seasonal influenza vaccine.

Ehrlich HJ, Berezuk G, Fritsch S, Aichinger G, Singer J, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN.

Vaccine. 2012 Jun 19;30(29):4377-86. doi: 10.1016/j.vaccine.2011.11.114. Epub 2011 Dec 13.

PMID:
22172502
22.

Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial.

Aichinger G, Ehrlich HJ, Aaskov JG, Fritsch S, Thomasser C, Draxler W, Wolzt M, Müller M, Pinl F, Van Damme P, Hens A, Levy J, Portsmouth D, Holzer G, Kistner O, Kreil TR, Barrett PN.

Vaccine. 2011 Nov 21;29(50):9376-84. doi: 10.1016/j.vaccine.2011.09.125. Epub 2011 Oct 12.

PMID:
22001875
23.

H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model.

Howard MK, Sabarth N, Savidis-Dacho H, Portsmouth D, Kistner O, Kreil TR, Ehrlich HJ, Barrett PN.

PLoS One. 2011;6(8):e23791. doi: 10.1371/journal.pone.0023791. Epub 2011 Aug 18.

24.

Developing cell culture-derived pandemic vaccines.

Barrett PN, Portsmouth D, Ehrlich HJ.

Curr Opin Mol Ther. 2010 Feb;12(1):21-30. Review.

PMID:
20140813
25.

Influence of vector design and host cell on the mechanism of recombination and emergence of mutant subpopulations of replicating retroviral vectors.

Paar M, Klein D, Salmons B, Günzburg WH, Renner M, Portsmouth D.

BMC Mol Biol. 2009 Feb 9;10:8. doi: 10.1186/1471-2199-10-8.

26.

Family at last: highlights of the first international meeting on proteins killing tumour cells.

Bruno P, Brinkmann CR, Boulanger MC, Flinterman M, Klanrit P, Landry MC, Portsmouth D, Borst J, Tavassoli M, Noteborn M, Backendorf C, Zimmerman RM.

Cell Death Differ. 2009 Jan;16(1):184-6. doi: 10.1038/cdd.2008.164. No abstract available.

27.
28.
29.

Suicide genes for cancer therapy.

Portsmouth D, Hlavaty J, Renner M.

Mol Aspects Med. 2007 Feb;28(1):4-41. Epub 2007 Jan 10. Review.

PMID:
17306358
30.

Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors.

Metzl C, Mischek D, Salmons B, Günzburg WH, Renner M, Portsmouth D.

J Virol. 2006 Jul;80(14):7070-8.

31.

Effects of sequences of prokaryotic origin on titer and transgene expression in retroviral vectors.

Hlavaty J, Portsmouth D, Stracke A, Salmons B, Günzburg WH, Renner M.

Virology. 2004 Dec 5;330(1):351-60.

32.

Inhibition of telomerase by site-specific ribonucleases in gastric and esophageal adenocarcinoma.

Usselmann B, Portsmouth D, Barclay J, Morris AG, Nwokolo CU.

Dig Dis Sci. 2001 Dec;46(12):2666-72.

PMID:
11768258
33.

The peroxidase activity of deuterohemin.

Portsmouth D, Beal EA.

Eur J Biochem. 1971 Apr 30;19(4):479-87. No abstract available.

34.

The chemistry of the modification of tryptophan with 2-hydroxy-5-nitrobenzyl bromide.

Loudon GM, Portsmouth D, Lukton A, Koshland DE Jr.

J Am Chem Soc. 1969 May 7;91(10):2792-4. No abstract available.

PMID:
5784953
35.

Studies on the mechanism of action of 2-keto-3-deoxy-L-arabonate dehydratase. The participation of an enzyme-substrate Schiff base in a dehydration.

Portsmouth D, Stoolmiller AC, Abeles RH.

J Biol Chem. 1967 Jun 10;242(11):2751-9. No abstract available.

36.

A synthesis of chromose D (3-O-acetyl-2,6-dideoxy-D-lyxo-hexose).

Brimacombe JS, Portsmouth D.

Chem Ind. 1965 Mar 13;11:468. No abstract available.

PMID:
5825537

Supplemental Content

Loading ...
Support Center